Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: A matched-pair analysis

Leukemia

Volumn 26, Issue 3, 2012, Pages 461-464

  Ishiyama, K ^a,b   Takami, A ^a   Kanda, Y ^c   Nakao, S ^a   Hidaka, M ^d   Maeda, T ^e   Naoe, T ^f   Taniguchi, S ^g   Kawa, K ^h   Nagamura, T ⁱ   Atsuta, Y ^j   Sakamaki, H ^k  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^e OSAKA UNIVERSITY HOSPITAL   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TORANOMON HOSPITAL   (Japan)

^h RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

more..

Author keywords

acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; t(6; 9)(p23; q34); unfavorable cytogenetic risk

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84858001909     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.229     Document Type: Article

References (13)

1. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-1321. (Pubitemid 350076512)
2. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-223.
3. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005; 103: 1652-1658. (Pubitemid 40490026)
4. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240. (Pubitemid 36988027)
5. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K et al. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood 2011; 117: 2113-2120.
6. The Medical Research Council Adult and Children's Leukaemia Working PartiesGrimwade D Walker H Oliver F Wheatley K Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
7. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
8. van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge RM et al. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica 2005; 90: 1339-1345. (Pubitemid 41503649)
9. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006; 20: 1295-1297. (Pubitemid 43905836)
10. Garcon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C et al. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 2005; 19: 1338-1344. (Pubitemid 41136325)
11. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
12. Gupta M, Ashok Kumar J, Sitaram U, Neeraj S, Nancy A, Balasubramanian P et al. The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. Cancer Genet Cytogenet 2010; 203: 297-302.
13. Esteve J, Labopin M, Socie G, Ljungman PT, Maertens J, Schattenberg AV et al. Allogeneic hematopoietic stem-cell transplantation in early phase might overcome the adverse prognosis of acute myeloid leukemia with translocation t(6;9)(p23;q34)/DEK-NUP214(CAN) rearrangement. A retrospective analysis from the acute leukemia working party of EBMT. Blood 2010; 116: 1438 (Abstract 3501).